Table 2 Characteristics of the population according to LVH

Age, years

58 ± 14

60 ± 15

NS

Male sex, n (%)

91 (56)

45(60)

NS

BMI, Kg/m²

26.1 ± 3.6

25.2 ± 3.3

NS

Diabetes, n (%)

29 (18)

12 (16)

NS

Dyslipidaemia, n (%)

64 (38)

33 (41)

NS

Clinic SBP, mmHg

144 ± 17

146 ± 18

NS

Clinic DBP, mmHg

87 ± 9

87 ± 10

NS

24 h mean SBP, mmHg

130 ± 14

131 ± 12

NS

24 h mean DBP, mmHg

79 ± 9

77 ± 9

NS

Echocardiographic data

IVSd, mm

9.5 ± 1.1

11.2 ± 1.6

< 0.001

LVPWd, m

9 ± 1.2

11.1 ± 1.5

< 0.001

RWT

0.38 ± 0.05

0.45 ± 0.07

< 0.001

LVEDd, mm

48 ± 4

50 ± 4

0.011

LV mass, g

150.6 ± 32.7

206.9 ± 48.3

< 0.001

LV mass/BSA, g/m²

80.6 ± 13.4

113.8 ± 22.9

< 0.001

LV mass/h^2,7, g/m^2,7

33.2 ± 10

50.5 ± 10

< 0.001

LA vol/h2, ml/m2

14.0 ± 2.0

18.6 ± 4.1

< 0.001

LVEF, %

68 ± 10

69 ± 10

NS

Pharmacological therapy

ACEi, n (%)

35 (21)

10 (13)

0.032

ARB, n (%)

67 (43)

38 (48)

NS

Calcium channel blockers, n (%)

60 (36)

31 (39)

NS

HCTZ, n (%)

45 (27)

18 (23)

NS

Beta-blockers, n (%)

40 (24)

15 (19)

NS

MRA, n (%)

9 (5)

2 (3)

NS

Combination therapy, n (%)

88 (53)

38 (48)

NS